Promoter methylation of SFRP3 is frequent in hepatocellular carcinoma

Disease Markers

Volumn 2014, Issue , 2014, Pages

  Lin, Ya Wen ^a   Shih, Yu Lueng ^b   Lien, Gi Shih ^c   Suk, Fat Moon ^c   Hsieh, Chung Bao ^b   Yan, Ming De ^c  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MEMBRANE PROTEIN; SECRETED FRIZZLED RELATED PROTEIN 3; UNCLASSIFIED DRUG; FRZB PROTEIN; GLYCOPROTEIN;

BISULFITE SEQUENCING; CANCER CELL CULTURE; CHRONIC HEPATITIS; CONTROLLED STUDY; DEMETHYLATION; DOWN REGULATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEQUENCE ANALYSIS; CASE CONTROL STUDY; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; HEMANGIOMA; LIVER; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DNA METHYLATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HEMANGIOMA; HUMANS; LIVER; LIVER NEOPLASMS; PROMOTER REGIONS, GENETIC;

EID: 84893750531     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2014/351863     Document Type: Review

References (40)

1. Bosch F. X., Ribes J., Cléries R., Díaz M., Epidemiology of hepatocellular carcinoma. Clinics in Liver Disease 2005 9 2 191 211 2-s2.0-17044371509 10.1016/j.cld.2004.12.009
2. Bosch F. X., Ribes J., Borràs J., Epidemiology of primary liver cancer. Seminars in Liver Disease 1999 19 3 271 285 2-s2.0-0032833628 (Pubitemid 29488770)
3. Befeler A. S., Di Bisceglie A. M., Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002 122 6 1609 1619 2-s2.0-0036096420 (Pubitemid 34533556)
4. El-Serag H. B., Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004 127 S27 S34 2-s2.0-7044231396 10.1053/j.gastro. 2004.09.013 (Pubitemid 39423367)
5. El-Serag H. B., Mason A. C., Rising incidence of hepatocellular carcinoma in the United States. The New England Journal of Medicine 1999 340 10 745 750 2-s2.0-0033545541 10.1056/NEJM199903113401001 (Pubitemid 29114292)
6. Thompson M. D., Monga S. P. S., WNT/ β -catenin signaling in liver health and disease. Hepatology 2007 45 5 1298 1305 2-s2.0-34248674146 10.1002/hep.21651 (Pubitemid 46775794)
7. Chiba T., Zheng Y.-W., Kita K., Yokosuka O., Saisho H., Onodera M., Miyoshi H., Nakano M., Zen Y., Nakanuma Y., Nakauchi H., Iwama A., Taniguchi H., Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 2007 133 3 937 950 2-s2.0-34548471937 10.1053/j.gastro.2007.06.016 (Pubitemid 47374130)
8. Zeng G., Apte U., Cieply B., Singh S., Monga S. P. S., siRNA-mediated β -catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia 2007 9 11 951 959 2-s2.0-36048967529 10.1593/neo.07469 (Pubitemid 350086440)
9. Behari J., The Wnt/ β -catenin signaling pathway in liver biology and disease. Expert Review of Gastroenterology and Hepatology 2010 4 6 745 756 2-s2.0-78649670044 10.1586/egh.10.74
10. Cadigan K. M., Nusse R., Wnt signaling: a common theme in animal development. Genes and Development 1997 11 24 3286 3305 2-s2.0-0031456158 (Pubitemid 28023954)
11. Logan C. Y., Miller J. R., Ferkowicz M. J., McClay D. R., Nuclear β -catenin is required to specify vegetal cell fates in the sea urchin embryo. Development 1999 126 2 345 357 2-s2.0-0032914194 (Pubitemid 29083972)
12. Polakis P., Wnt signaling and cancer. Genes and Development 2000 14 15 1837 1851 2-s2.0-0033895709 (Pubitemid 30639518)
13. Yost C., Torres M., Miller J. R., Huang E., Kimelman D., Moon R. T., The axis-inducing activity, stability, and subcellular distribution of β -catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes and Development 1996 10 12 1443 1454 2-s2.0-0029683606 (Pubitemid 26260702)
14. Behrens J., von Kries J. P., Kühl M., Bruhn L., Wedlich D., Grosschedl R., Birchmeier W., Functional interaction of β -catenin with the transcription factor LEF- 1. Nature 1996 382 6592 638 642 2-s2.0-0029781509 10.1038/382638a0 (Pubitemid 26268958)
15. Cui J., Zhou X., Liu Y., Tang Z., Romeih M., Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes. Journal of Gastroenterology and Hepatology 2003 18 3 280 287 2-s2.0-0037367866 10.1046/j.1440-1746.2003.02973.x (Pubitemid 36519145)
16. de La Coste A., Romagnolo B., Billuart P., Renard C.-A., Buendia M.-A., Soubrane O., Fabre M., Chelly J., Beldjord C., Kahn A., Perret C., Somatic mutations of the β -catenin gene are frequent in mouse and human hepatocellular carcinomas. Proceedings of the National Academy of Sciences of the United States of America 1998 95 15 8847 8851 2-s2.0-0345006147 10.1073/pnas.95.15.8847 (Pubitemid 28350577)
17. Farazi P. A., DePinho R. A., Hepatocellular carcinoma pathogenesis: from genes to environment. Nature Reviews Cancer 2006 6 9 674 687 2-s2.0-33747830764 10.1038/nrc1934 (Pubitemid 44286000)
18. Shih Y.-L., Shyu R.-Y., Hsieh C.-B., Lai H.-C., Liu K.-Y., Chu T.-Y., Lin Y.-W., Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer 2006 107 3 579 590 2-s2.0-33746296615 10.1002/cncr.22023 (Pubitemid 44107219)
19. Caldwell G. M., Jones C., Gensberg K., Jan S., Hardy R. G., Byrd P., Chughtai S., Wallis Y., Matthews G. M., Morton D. G., The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Research 2004 64 3 883 888 2-s2.0-10744229341 10.1158/0008-5472.CAN-03-1346 (Pubitemid 38176888)
20. Sarrió D., Moreno-Bueno G., Hardisson D., Sánchez- Estévez C., Guo M., Herman J. G., Gamallo C., Esteller M., Palacios J., Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. International Journal of Cancer 2003 106 2 208 215 2-s2.0-0037479867 10.1002/ijc.11197 (Pubitemid 36835173)
21. Satoh S., Daigo Y., Furukawa Y., Kato T., Miwa N., Nishiwaki T., Kawasoe T., Ishiguro H., Fujita M., Tokino T., Sasaki Y., Imaoka S., Murata M., Shimano T., Yamaoka Y., Nakamura Y., AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nature Genetics 2000 24 3 245 250 2-s2.0-0034088858 10.1038/73448 (Pubitemid 30132191)
22. Suzuki H., Gabrielson E., Chen W., Anbazhagan R., Van Engeland M., Weijenberg M. P., Herman J. G., Baylin S. B., A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nature Genetics 2002 31 2 141 149 2-s2.0-0036613250 10.1038/ng892
23. Herman J. G., Baylin S. B., Gene silencing in cancer in association with promoter hypermethylation. The New England Journal of Medicine 2003 349 21 2042 2054 2-s2.0-0345357773 10.1056/NEJMra023075 (Pubitemid 37448928)
24. Herman J. G., Merlo A., Mao L., Lapidus R. G., Issa J.-P. J., Davidson N. E., Sidransky D., Baylin S. B., Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Research 1995 55 20 4525 4530 2-s2.0-0028845142
25. Esteller M., Sparks A., Toyota M., Sanchez-Cespedes M., Capella G., Peinado M. A., Gonzalez S., Tarafa G., Sidransky D., Meltzer S. J., Baylin S. B., Herman J. G., Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Research 2000 60 16 4366 4371 2-s2.0-0034662626 (Pubitemid 32103613)
26. Yu J., Zhang H. Y., Ma Z. Z., Lu W., Wang Y. F., Zhu J. D., Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Research 2003 13 5 319 333 2-s2.0-1542322897 10.1038/sj.cr.7290177 (Pubitemid 43231848)
27. Yang B., Guo M., Herman J. G., Clark D. P., Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. American Journal of Pathology 2003 163 3 1101 1107 2-s2.0-0041924707 (Pubitemid 37040145)
28. Schagdarsurengin U., Wilkens L., Steinemann D., Flemming P., Kreipe H. H., Pfeifer G. P., Schlegelberger B., Dammann R., Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 2003 22 12 1866 1871 2-s2.0-0037468934 10.1038/sj.onc.1206338 (Pubitemid 36513145)
29. Suzuki H., Watkins D. N., Jair K.-W., Schuebel K. E., Markowitz S. D., Chen W. D., Pretlow T. P., Yang B., Akiyama Y., Van Engeland M., Toyota M., Tokino T., Hinoda Y., Imai K., Herman J. G., Baylin S. B., Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nature Genetics 2004 36 4 417 422 2-s2.0-12144291274 10.1038/ng1330 (Pubitemid 38437267)
30. Finch P. W., He X., Kelley M. J., Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proceedings of the National Academy of Sciences of the United States of America 1997 94 6770 6775 (Pubitemid 27281939)
31. Ekström E. J., Sherwood V., Andersson T., Methylation and loss of secreted frizzled-related protein 3 enhances melanoma cell migration and invasion. PLoS ONE 2011 6 4 2-s2.0-79954556422 10.1371/journal.pone.0018674 e18674
32. Zi X., Guo Y., Simoneau A. R., Hope C., Xie J., Holcombe R. F., Hoang B. H., Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Research 2005 65 21 9762 9770 2-s2.0-27544496133 10.1158/0008-5472.CAN-05-0103 (Pubitemid 41541453)
33. Hirata H., Hinoda Y., Ueno K., Majid S., Saini S., Dahiya R., Role of secreted frizzled-related protein 3 in human renal cell carcinoma. Cancer Research 2010 70 5 1896 1905 2-s2.0-77950190313 10.1158/0008-5472.CAN-09-3549
34. Shih Y.-L., Hsieh C.-B., Lai H.-C., Yan M.-D., Hsieh T.-Y., Chao Y.-C., Lin Y.-W., SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway. International Journal of Cancer 2007 121 5 1028 1035 2-s2.0-34547093863 10.1002/ijc.22750 (Pubitemid 47101639)
35. Herman J. G., Graff J. R., Myöhänen S., Nelkin B. D., Baylin S. B., Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proceedings of the National Academy of Sciences of the United States of America 1996 93 18 9821 9826 2-s2.0-0029843950 10.1073/pnas.93.18.9821 (Pubitemid 26296693)
36. Ogino S., Kawasaki T., Brahmandam M., Cantor M., Kirkner G. J., Spiegelman D., Makrigiorgos G. M., Weisenberger D. J., Laird P. W., Loda M., Fuchs C. S., Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. Journal of Molecular Diagnostics 2006 8 2 209 217 2-s2.0-33744550591 10.2353/jmoldx.2006.050135 (Pubitemid 43811244)
37. Lai H.-C., Lin Y.-W., Huang R.-L., Chung M.-T., Wang H.-C., Liao Y.-P., Su P.-H., Liu Y.-L., Yu M.-H., Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and worse. Cancer 2010 116 18 4266 4274 2-s2.0-77957339798 10.1002/cncr.25252
38. Coleman W. B., Rivenbark A. G., Quantitative DNA methylation analysis: the promise of high-throughput epigenomic diagnostic testing in human neoplastic disease. Journal of Molecular Diagnostics 2006 8 2 152 156 2-s2.0-33744527879 10.2353/jmoldx.2006.060026 (Pubitemid 43811237)
39. Livak K. J., Schmittgen T. D., Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001 25 4 402 408 2-s2.0-0035710746 10.1006/meth.2001.1262 (Pubitemid 34164012)
40. Kondo Y., Kanai Y., Sakamoto M., Mizokami M., Ueda R., Hirohashi S., Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis-a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 2000 32 5 970 979 2-s2.0-0033765496